Quantification of heart fatty acid binding protein as a biomarker for drug-induced cardiac and musculoskeletal necroses |
| |
Authors: | Zhen Eugene Y Berna Michael J Jin Zhaoyan Pritt Michael L Watson David E Ackermann Bradley L Hale John E |
| |
Affiliation: | Integrative Biology, Lilly Research Laboratories, Eli Lilly & Company, Greenfield, IN, USA. zhen@lilly.com. |
| |
Abstract: | Heart fatty acid binding protein (Fabp3) is a cytosolic protein expressed primarily in heart, and to a lesser extent in skeletal muscle, brain, and kidney. During myocardial injury, the Fabp3 level in serum is elevated rapidly, making it an ideal early marker for myocardial infarction. In this study, an MS‐based selected reaction monitoring method (LC‐SRM) was developed for quantifying Fabp3 in rat serum. Fabp3 was enriched first through an immobilized antibody, and the protein was digested on beads directly. A marker peptide of Fabp3 was quantified using LC‐SRM with a stable isotope‐labeled peptide standard. For six quality control samples with Fabp3 ranging from 0.256 to 25 ng, the average recovery following the procedure was about 73%, and the precision (%CV) between replicates was less than 7%. The Fabp3 concentrations in rat serum peaked 1 h after isoproterenol treatment, and returned to baseline levels 24 h after the dose. Elevated Fabp3 levels were also detected in rats administered with a PPAR α/δ agonist, which has shown to cause skeletal muscle necrosis. Fabp3 can be used as a biomarker for both cardiac and skeletal necroses. The cross‐validation of the LC‐SRM method with an existing ELISA method is described. |
| |
Keywords: | Biomarker Cardiac toxicity Heart fatty acid binding protein LC‐SRM |
本文献已被 PubMed 等数据库收录! |
|